Resverlogix (TSE:RVX) Trading Up 16.7% – What’s Next?
by Teresa Graham · The Cerbat GemResverlogix Corp. (TSE:RVX – Get Free Report)’s share price was up 16.7% on Wednesday . The stock traded as high as C$0.07 and last traded at C$0.07. Approximately 197,830 shares were traded during trading, an increase of 225% from the average daily volume of 60,927 shares. The stock had previously closed at C$0.06.
Resverlogix Stock Down 7.1 %
The firm has a 50 day moving average price of C$0.07 and a two-hundred day moving average price of C$0.06. The company has a market capitalization of C$18.00 million, a price-to-earnings ratio of -1.30 and a beta of 0.71.
Resverlogix (TSE:RVX – Get Free Report) last announced its earnings results on Wednesday, August 14th. The biotechnology company reported C($0.02) earnings per share for the quarter. Analysts predict that Resverlogix Corp. will post -0.22 earnings per share for the current year.
About Resverlogix
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Resverlogix
- Differences Between Momentum Investing and Long Term Investing
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Why Invest in 5G? How to Invest in 5G Stocks
- 4 Quirky ETFs With Big Potential for Impressive Gains